Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.
Tu Megan M, Ng Terry L, De Jong Florus C, +3 more·Bladder cancer (Amsterdam, Netherlands)
BACKGROUND: The activity of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer (BC) is promising for many patients. However, a subset of patients do not benefit from treatment, thus leading to an effort to better identify predictive molecular biomarkers of response. OBJECTIVE: To conduct a systematic re…